KROS
Keros Therapeutics Inc

1,232
Mkt Cap
$505.13M
Volume
167,955.00
52W High
$22.55
52W Low
$9.12
PE Ratio
10.75
KROS Fundamentals
Price
$16.52
Prev Close
$16.58
Open
$16.65
50D MA
$19.33
Beta
0.90
Avg. Volume
355,487.40
EPS (Annual)
-$5.00
P/B
0.96
Rev/Employee
$21,005.92
$51.57
Loading...
Loading...
News
all
press releases
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have been assigned an average rating of "Hold" from the ten analysts that are covering the company, MarketBeat.com reports. One...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.
Zacks·14d ago
News Placeholder
Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS
Y Intercept Hong Kong Ltd reduced its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 53.7% during the 3rd quarter, according to the company in its most recent 13F...
MarketBeat·14d ago
News Placeholder
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
Zacks·21d ago
News Placeholder
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
Keros Therapeutics advances KER-065 toward DMD trials, trims costs, and extends its cash runway as investors weigh it against Dyne???s deeper pipeline
Zacks·21d ago
News Placeholder
Is KROS' KER-065 the Next Breakthrough in DMD Space?
KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.
Zacks·22d ago
News Placeholder
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.
Zacks·26d ago
News Placeholder
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.
Zacks·26d ago
News Placeholder
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has received a consensus rating of "Hold" from the ten research firms that are currently covering the company, Marketbeat.com reports. One...
MarketBeat·27d ago
News Placeholder
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.
Zacks·27d ago
<
1
2
...
>

Latest KROS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.